Treatments studied

Breakdown from sources

Darunavir

Nelfinavir

Saquinavir

Rosuvastatin

Montelukast

Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning

Ayman Farag Ping Wang Mahmoud Ahmed Hesham Sadek

Preprint

listed on

6.4.2020

Aliskiren

Dipyridamole

Mopidamol

Rolitetracycling

Rosuvastatin

Molecular Docking Reveals the Potential of Aliskiren, Dipyridamole, Mopidamol, Rosuvastatin, Rolitetracycline and Metamizole to Inhibit COVID-19 Virus Main Protease

Omar Aly

Preprint

listed on

6.4.2020

remdesivir

nafamostat

ribavirin

camptothecin

vinca

Drug Repurposing Approach Targeted Against Main Protease of SARS-CoV-2 Exploiting ‘Neighbourhood Behaviour’ in 3D Protein Structural Space and 2D Chemical Space of Small Molecules

Sohini Chakraborti, Narayanaswamy Srinivasan

Preprint

listed on

6.4.2020

Simeprevir

Paritaprevir

Remdesivir

Baricitinib

Comparative Computational Study of SARS-CoV-2 Receptors Antagonists from Already Approved Drugs

Micael Davi Lima de Oliveira, Kelson Mota Teixeira de Oliveira

Preprint

listed on

6.4.2020

Nelfinavir

Nelfinavir Is Active Against SARS-CoV-2 in Vero E6 Cells

Zhijian Xu Hangping Yao Jingshan Shen Nanping Wu Yechun Xu Xiangyun Lu weiliang zhu Lan-Juan Li

Preprint

listed on

6.4.2020

Lasinavir

Brecanavir

Telinavir

Rotigaptide

Pimelautide

Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of COVID-19 Main Protease: A Virtual Drug Repurposing Study

Serdar Durdagi Busecan Aksoydan Berna Dogan Kader Sahin Aida Shahraki

Preprint

listed on

6.4.2020

Sildenafil

Ionomycin

Losartan

Nitroglycerin

Bezafibrate

NOS+SARS-CoV-2 Pathogenesis

Roman Gurinovich, Yuliya Buinitskaya

Preprint

listed on

6.4.2020

Remdesivir

Sharing vital research to help prevent and treat cases of coronavirus

Wenshe Ray Liu, Megan Hardeman

online resource

listed on

30.3.2020

Remdesivir

3CLpro-1

RBD

ACE2

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV

Jared S. Morse, Tyler Lalonde, Shiqing Xu, Wenshe Liu

preprint

listed on

30.3.2020

Ledipasvir

Velpatasvir

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like Protease (3CLpro) Structure: Virtual Screening Reveals Velpatasvir, Ledipasvir, and Other Drug Repurposing Candidates

Yu Wai Chen Chin-Pang Yiu Kwok-Yin Wong

preperint

listed on

30.3.2020

Treatments studied

Substances / Treatments

Proportion

Breakdown from sources

Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning

Molecular Docking Reveals the Potential of Aliskiren, Dipyridamole, Mopidamol, Rosuvastatin, Rolitetracycline and Metamizole to Inhibit COVID-19 Virus Main Protease

Drug Repurposing Approach Targeted Against Main Protease of SARS-CoV-2 Exploiting ‘Neighbourhood Behaviour’ in 3D Protein Structural Space and 2D Chemical Space of Small Molecules

Comparative Computational Study of SARS-CoV-2 Receptors Antagonists from Already Approved Drugs

Nelfinavir Is Active Against SARS-CoV-2 in Vero E6 Cells

Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of COVID-19 Main Protease: A Virtual Drug Repurposing Study

NOS+SARS-CoV-2 Pathogenesis

Sharing vital research to help prevent and treat cases of coronavirus

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like Protease (3CLpro) Structure: Virtual Screening Reveals Velpatasvir, Ledipasvir, and Other Drug Repurposing Candidates

Other related sources

COVID-19 vaccine candidates: Prediction and validation of 174 novel SARS-CoV-2 epitopes